BLB&B Advisors LLC Sells 2,906 Shares of AbbVie Inc. $ABBV

BLB&B Advisors LLC reduced its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 3.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 84,650 shares of the company’s stock after selling 2,906 shares during the period. AbbVie comprises approximately 0.8% of BLB&B Advisors LLC’s portfolio, making the stock its 28th biggest holding. BLB&B Advisors LLC’s holdings in AbbVie were worth $19,342,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Evolution Wealth Management Inc. purchased a new stake in shares of AbbVie in the 2nd quarter valued at $26,000. Chelsea Counsel Co. purchased a new position in AbbVie in the 3rd quarter worth $26,000. Westend Capital Management LLC purchased a new position in AbbVie in the 4th quarter worth $29,000. Texas Capital Bancshares Inc TX bought a new stake in AbbVie in the third quarter worth $31,000. Finally, Caitlin John LLC purchased a new stake in AbbVie during the third quarter valued at about $33,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie Stock Up 1.9%

Shares of AbbVie stock opened at $210.29 on Wednesday. The company’s fifty day simple moving average is $219.66 and its two-hundred day simple moving average is $223.88. AbbVie Inc. has a 12-month low of $168.54 and a 12-month high of $244.81. The firm has a market cap of $371.83 billion, a PE ratio of 89.11, a price-to-earnings-growth ratio of 0.73 and a beta of 0.38.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.65 by $0.06. The firm had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The company’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, sell-side analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a yield of 3.3%. AbbVie’s dividend payout ratio is presently 293.22%.

Insider Activity at AbbVie

In related news, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the transaction, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of the firm’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the sale, the senior vice president directly owned 2,654 shares of the company’s stock, valued at $619,868.24. The trade was a 66.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.06% of the company’s stock.

Analysts Set New Price Targets

ABBV has been the topic of a number of recent research reports. Guggenheim raised their price objective on AbbVie from $242.00 to $249.00 and gave the company a “buy” rating in a research note on Friday, April 10th. The Goldman Sachs Group reissued a “neutral” rating and issued a $223.00 target price on shares of AbbVie in a research note on Wednesday, January 28th. Piper Sandler increased their target price on AbbVie from $289.00 to $299.00 and gave the company an “overweight” rating in a report on Wednesday, February 18th. Berenberg Bank set a $275.00 price target on AbbVie in a research report on Tuesday, January 20th. Finally, Citigroup decreased their price target on AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 27th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $253.00.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Late‑breaking Phase 2 data showed Elahere (mirvetuximab) demonstrated efficacy and safety in platinum‑sensitive ovarian cancer — news that strengthens AbbVie’s oncology story and could support future uptake/launch value. AbbVie Ovarian Cancer Data And Pain Deal Extend Long Term Story
• Positive Sentiment: AbbVie struck an exclusive licensing deal with China’s Haisco for pain assets (deal reported up to ~$715–745M), giving AbbVie global rights outside China and expanding its pain pipeline — a near‑term catalyst for pipeline diversification and future revenue optionality. AbbVie inks $715M deal with Chinese biotech Haisco
• Positive Sentiment: An analyst price target lift to $249 signals bullish sell‑side sentiment and likely supports buying interest. AbbVie (NYSE:ABBV) Price Target Raised to $249.00
• Positive Sentiment: AbbV-438 myeloma Phase 1 update highlights AbbVie’s early‑stage oncology investments — an incremental positive for long‑term oncology growth, though clinical risk remains. AbbVie’s ABBV-438 Myeloma Trial: Early-Stage Bet on Long-Term Oncology Growth
• Neutral Sentiment: Analysts and coverage pieces note neuroscience brands (Botox, Vraylar) are expected to help Q1 top‑line performance — supportive but dependent on execution and pricing dynamics. Will AbbVie’s Neuroscience Franchise Aid Top-line Growth in Q1?
• Neutral Sentiment: Coverage on AbbVie entering the weight‑loss arena notes progress but says the company remains behind leaders (e.g., Lilly) — a mixed signal on competitive positioning in metabolic/weight‑loss space. Could AbbVie Crash Lilly’s Weight‑Loss Party?
• Neutral Sentiment: Marketing/aesthetics PR (Natrelle breast‑implant campaign) increases brand visibility for Allergan Aesthetics, useful for the consumer/aesthetics business but unlikely to move fundamentals materially. Erin Lichy Gets Real About Her Natrelle® Breast Augmentation

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.